Loading clinical trials...
Loading clinical trials...
A Phase II, Multicentre, Parallel Group, Open Label, Randomised Clinical Trial of Neoadjuvant Nivolumab and Ipilimumab Combined With Relatlimab for Patients With Resectable Advanced Melanoma Identified as Poor Responders to Immunotherapy
Conditions
Interventions
Ipilimumab 3mg/kg and nivolumab 1mg/kg
Ipilimumab 1mg/kg Nivolumab 480mg and relatlimab 160mg
+3 more
Locations
1
Australia
Melanoma Institute Australia
Wollstonecraft, New South Wales, Australia
Start Date
February 9, 2026
Primary Completion Date
March 1, 2028
Completion Date
January 1, 2038
Last Updated
February 19, 2026
NCT05111574
NCT05039801
NCT06391099
NCT07076550
NCT06673095
NCT07230613
Lead Sponsor
Melanoma Institute Australia
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions